Tranquis Therapeutics is a clinical-stage biopharmaceutical company focusing on developing small molecule therapies for neurodegenerative diseases and immune-related disorders. They are pioneering a novel approach by targeting immune cells, specifically myeloid cells, which play a crucial role in inflammation and disease progression in the nervous system. Their flagship program, TQS-168, aims to restore metabolic pathways in these cells, with potential applications in conditions like ALS (Amyotrophic Lateral Sclerosis) and FTD (Frontotemporal Dementia). Tranquis’ approach is grounded in immunometabolism, aiming to regulate the inflammatory response to improve disease outcomes.